Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice - PubMed (original) (raw)

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Thomas A Lagace et al. J Clin Invest. 2006 Nov.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Pulse-chase analysis of endogenous PCSK9 secretion from HepG2 cells.

Cells were cultured in sterol-depleting medium C for 18 hours prior to labeling for 30 minutes with [35S]methionine/cysteine. After washing, cells were incubated in chase medium containing unlabeled methionine and cysteine for the indicated times. Cells were lysed, and PCSK9 was immunoprecipitated from the medium and cell lysates as described in Methods. Samples were subjected to 8% SDS-PAGE, and the gel was treated with Amplify fluorogenic reagent prior to drying and exposure to film. P and C denote the proprotein and cleaved forms of PCSK9, respectively. Similar results were obtained in 4 independent experiments.

Figure 2

Figure 2. Reduction of endogenous LDLRs in HepG2 cells following the addition of recombinant purified PCSK9 to the culture medium.

(A) Dose response of exogenous PCSK9-mediated LDLR degradation in HepG2 cells. Cells were cultured for 18 hours in medium C prior to treatment for 4 hours with the indicated amounts of purified human PCSK9. (B) Time course of exogenous PCSK9-mediated LDLR degradation. HepG2 cells cultured as described above were treated with 5 μg/ml of purified PCSK9 for the indicated times. Total lysates were prepared following cell-surface biotinylation as described in Methods. Proteins were subjected to SDS-PAGE for immunoblot analysis of the LDLR using IgG-HL1 and anti–FLAG M2 monoclonal antibody to detect purified PCSK9. The transferrin receptor protein was detected as described in Methods and used as a control for loading and nonspecific protein degradation. Similar results were obtained in 3 independent experiments.

Figure 3

Figure 3. Increased cell association and LDLR degradation by addition of purified mutant PCSK9(D374Y) to the medium of HepG2 cells.

Cells were cultured for 18 hours in medium C and then incubated for 4 hours with the indicated amounts of purified human PCSK9 or PCSK9(D374Y). Immunoblot analysis of LDLR, FLAG-tagged PCSK9, and transferrin receptor was carried out as described in the legend to Figure 2. The asterisk indicates a nonspecific band. Similar results were obtained in 3 independent experiments.

Figure 4

Figure 4. LDLR-dependent endocytosis of PCSK9 in MEFs.

(A) Immunoblot analysis of PCSK9 association with MEFs. Immortalized MEFs derived from wild-type, Ldlr–/–, Lrp–/–, and _Ldlr–/–Lrp–/–_mice were cultured for 18 hours in medium F prior to treatment with purified human PCSK9 for 4 hours. Cell lysates (30 μg) were subjected to SDS-PAGE and immunoblot analysis using IgG-15A6 to detect PCSK9 or a polyclonal antiserum (Ab 3143) that recognizes the LDLR, as described in Methods. Immunoblots of receptor-associated protein (RAP) were used as a loading control. (B) Indirect immunofluorescence localization of PCSK9 and the LDLR in wild-type MEFs. MEFs were incubated for 4 hours with 5 μg/ml purified human PCSK9 and processed for double immunofluorescence of PCSK9 (green) and the LDLR (red) as described in Methods. (C) Indirect immunofluorescence localization of PCSK9, LDLR, and the late-endosomal marker CI-MPR in MEFs cultured in the presence of chloroquine. Wild-type MEFs were incubated for 4 hours with 5 μg/ml purified human PCSK9 in the presence of 0.1 mM chloroquine and processed for double immunofluorescence of PCSK9 (green) and the LDLR (red) or CI-MPR (red) as described in Methods. The merged image shows areas of colocalization of PCSK9 with the LDLR and CI-MPR. Magnification, ×630. Similar results were obtained in 3 independent experiments.

Figure 5

Figure 5. Association of PCSK9 and PCSK9(D374Y) with the LDLR.

(A) Coimmunoprecipitation of the LDLR and exogenously added wild-type PCSK9 or PCSK9(D374Y) protein. HepG2 cells were cultured for 18 hours in medium C prior to treatment for 1 hour in the presence of 0.1 mM chloroquine with 20 μg/ml or 2 μg/ml of purified human PCSK9 or PCSK9(D374Y), respectively. Cells were harvested and lysed and proteins immunoprecipitated with the indicated antibodies. Pellets of the immunoprecipitation were subjected to SDS-PAGE and immunoblot analysis. Polyclonal antiserum (Ab 3143) was used to detect LDLR, and IgG-15A6 was used to detect PCSK9. (B) Reduced (R) or nonreduced (NR) LDLR extracellular domain protein (2 μg) was resolved by SDS-PAGE. LDLR protein was detected with Coomassie brilliant blue R-250 stain. (C) Binding of PCSK9 to LDLR on ligand blots. LDLR protein (2 μg) was transferred to nitrocellulose and incubated with 5 μg/ml of purified PCSK9 or no addition (NA). Bound PCSK9 was detected by immunoblot analysis as described in Methods. (D) The indicated amounts of purified LDLR were subjected to nonreduced SDS-PAGE, transferred to nitrocellulose, and incubated with 5 μg/ml of purified wild-type PCSK9, PCSK9(D374Y), or buffer control (no addition). Bound PCSK9 was detected by immunoblot analysis as described in Methods. pep., FLAG octapeptide.

Figure 6

Figure 6. PCSK9-mediated degradation of the LDLR is dependent on ARH.

Immunofluorescence (A) and immunoblot (B) analyses of the PCSK9-mediated changes of LDLR protein in mouse primary hepatocytes derived from LDLRh/hArh+/+(Arh+/+) or LDLRh/hArh–/– (Arh–/–) mice. (A) Primary hepatocytes were incubated with no PCSK9 (–PCSK9) or with 5 μg/ml purified PCSK9 (+PCSK9) for 4 hours and processed for indirect immunofluorescence of LDLR using IgG-C7 and Alexa Fluor 563–conjugated secondary antibody, as described in Methods. Images were taken using a 63 × 1.3 objective using a confocal microscope (Leica TCS SP). Similar results were obtained in 2 independent experiments. (B) Immunoblot analysis of LDLR, FLAG-tagged PCSK9, transferrin receptor, and actin proteins in primary hepatocytes from mice of the indicated genotype incubated with varying amounts of PCSK9.

Figure 7

Figure 7. Decreased amounts of hepatic LDLR protein and increased levels of plasma LDL cholesterol in transgenic PCSK9 mice.

(A) Whole-cell lysates (30 μg) from livers of 5 wild-type and 5 TgPCSK9 mice were subjected to SDS-PAGE and immunoblot analyses of human PCSK9, mouse LDLR, and mouse ARH. (B) Plasma from the mice of each genotype described in A and from 5 age-matched male Ldlr–/– mice was pooled and subjected to gel filtration by fast performance liquid chromatography. The concentration of total cholesterol in each fraction was measured as described in Methods.

Figure 8

Figure 8. Amounts of LDLR protein in livers of parabiosed mice.

Three combinations of mice were parabiosed for study: wild-type:wild-type (A); Ldlr–/–:wild-type (B); and TgPCSK9:wild-type (C). Prior to parabiosis, a liver sample (<100 mg) via a partial hepatectomy and approximately 50 μl of blood via the tail vein were obtained from each mouse. After a 7-day recovery period, 12- to 20-week-old female mice of the indicated genotype were parabiosed as described in Methods. After 2 weeks of parabiosis, the animals were killed, and blood and liver samples were collected for analysis. Liver membrane protein (40 μg) obtained from each mouse before (–) and after (+) parabiosis was subjected to SDS-PAGE for immunoblot analyses of LDLR and RAP as a loading control (9).

Similar articles

Cited by

References

    1. Seidah N.G., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 2003;100:928–933. - PMC - PubMed
    1. Naureckiene S., et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 2003;420:55–67. - PubMed
    1. Benjannet S., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 2004;279:48865–48875. - PubMed
    1. Abifadel M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. . Nat. Genet. 2003;34:154–156. - PubMed
    1. Sun X.-M., et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum. Mol. Genet. 2005;14:1161–1169. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources